Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Receivables (2016 - 2026)

Aytu Biopharma has reported Receivables over the past 11 years, most recently at $30.9 million for Q4 2025.

  • Quarterly Receivables rose 21.73% to $30.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.9 million through Dec 2025, up 21.73% year-over-year, with the annual reading at $31.2 million for FY2025, 32.43% up from the prior year.
  • Receivables was $30.9 million for Q4 2025 at Aytu Biopharma, down from $33.2 million in the prior quarter.
  • Over five years, Receivables peaked at $35.8 million in Q1 2025 and troughed at $21.6 million in Q3 2021.
  • The 5-year median for Receivables is $29.4 million (2023), against an average of $28.3 million.
  • Year-over-year, Receivables surged 438.72% in 2021 and then decreased 25.83% in 2024.
  • A 5-year view of Receivables shows it stood at $23.0 million in 2021, then grew by 10.92% to $25.5 million in 2022, then rose by 15.31% to $29.4 million in 2023, then dropped by 13.6% to $25.4 million in 2024, then increased by 21.73% to $30.9 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Receivables are $30.9 million (Q4 2025), $33.2 million (Q3 2025), and $31.2 million (Q2 2025).